% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:859196,
      author       = {Galldiks, Norbert and Langen, Karl-Josef and Albert,
                      Nathalie L and Chamberlain, Marc and Soffietti, Riccardo and
                      Kim, Michelle M and Law, Ian and Le Rhun, Emilie and Chang,
                      Susan and Schwarting, Julian and Combs, Stephanie E and
                      Preusser, Matthias and Forsyth, Peter and Pope, Whitney and
                      Weller, Michael and Tonn, Jörg C},
      title        = {{PET} {I}maging in {P}atients with {B}rain {M}etastasis -
                      {R}eport of the {RANO}/{PET} {G}roup},
      journal      = {Neuro-Oncology},
      volume       = {21},
      number       = {5},
      issn         = {1523-5866},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2019-00086},
      pages        = {585-595},
      year         = {2019},
      abstract     = {Brain metastases (BM) from extracranial cancer are
                      associated with significant morbidity and mortality.
                      Effective local treatment options are stereotactic
                      radiotherapy, including radiosurgery or fractionated
                      external beam radiotherapy, and surgical resection. The use
                      of systemic treatment for intracranial disease control also
                      is improving. BM diagnosis, treatment planning, and
                      follow-up is most often based on contrast-enhanced magnetic
                      resonance imaging (MRI). However, anatomic imaging
                      modalities including standard MRI have limitations in
                      accurately characterizing posttherapeutic reactive changes
                      and treatment response. Molecular imaging techniques such as
                      positron emission tomography (PET) characterize specific
                      metabolic and cellular features of metastases, potentially
                      providing clinically relevant information supplementing
                      anatomic MRI. Here, the Response Assessment in
                      Neuro-Oncology working group provides recommendations for
                      the use of PET imaging in the clinical management of
                      patients with BM based on evidence from studies validated by
                      histology and/or clinical outcome.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30615138},
      UT           = {WOS:000473768600005},
      doi          = {10.1093/neuonc/noz003},
      url          = {https://juser.fz-juelich.de/record/859196},
}